AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
33.29
-0.28 (-0.83%)
At close: 4:04PM EST

33.39 +0.07 (0.22%)
After hours: 4:11PM EST

Stock chart is not supported by your current browser
Previous Close33.57
Open33.50
Bid31.00 x 900
Ask33.33 x 100
Day's Range33.19 - 33.60
52 Week Range26.51 - 35.60
Volume3,175,953
Avg. Volume3,559,593
Market Cap81.265B
Beta0.65
PE Ratio (TTM)21.84
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.90 (2.70%)
Ex-Dividend Date2017-08-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube3 days ago

    ETFs with exposure to AstraZeneca Plc : December 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AstraZeneca Plc Here are 5 ETFs with the largest exposure to AZN-US. Comparing the performance and risk of AstraZeneca Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • 3 High-Yield Dividend Stocks to Buy in 2018
    Motley Fool3 days ago

    3 High-Yield Dividend Stocks to Buy in 2018

    These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.

  • Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down
    Investor's Business Daily8 days ago

    Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down

    Clovis rose Wednesday to the detriment of Tesaro and AstraZeneca after the FDA accepted its application for expanded use of its PARP inhibitor known as Rubraca.

  • Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes
    Zacks8 days ago

    Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes

    Novo Nordisk (NVO) announced that the FDA approved semaglutide, which is a once-weekly injection approved to improve glycaemic control in adults with type II diabetes mellitus.

  • A Deadly Drug Cocktail Shines a Light on an AstraZeneca Blockbuster
    Bloomberg9 days ago

    A Deadly Drug Cocktail Shines a Light on an AstraZeneca Blockbuster

    Taking Seroquel with methadone can be fatal. Did the drugmaker’s warnings fall short?

  • Barrons.com9 days ago

    [$$] AstraZeneca Sells $10.7 Million in Albireo Stock

    AstraZeneca has halved its investment in Albireo Pharma. A subsidiary of AstraZeneca (ticker: AZN), AstraZeneca AB, sold 500,000 Albireo (ALBO) shares for $10.7 million, or $21.40 each on Dec. 1. AstraZeneca ...

  • FDA approves diabetes drug that also helps with weight loss
    Associated Press9 days ago

    FDA approves diabetes drug that also helps with weight loss

    TRENTON, N.J. (AP) — U.S. regulators on Tuesday approved a new diabetes drug that reduces blood sugar levels and also helps people lose significant weight.

  • Barrons.com9 days ago

    [$$] AstraZeneca Sells $6.6M in G1 Therapeutics Stock

    G1 Therapeutics, a clinical-stage oncology company, announced a collaboration with AstraZeneca Nov. 28. The pact will evaluate AstraZeneca’s (AZN) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso (osimertinib) in combination with G1’s (GTHX) oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). The press release didn’t mention that AstraZeneca, through its MedImmune Ventures subsidiary, is a significant shareholder in G1 nor that MedImmune Ventures has been selling G1 shares.

  • AstraZeneca's COPD Drug Succeeds in Label Expansion Study
    Zacks9 days ago

    AstraZeneca's COPD Drug Succeeds in Label Expansion Study

    AstraZeneca (AZN) releases positive top-line data from a phase IV study, evaluating label expansion of Tudorza for chronic obstructive pulmonary disease with cardiovascular risk factors.

  • Market Realist10 days ago

    Merck’s Diabetes Portfolio in 3Q17

    The combined revenues of Merck's (MRK) Januvia and Janumet in 3Q17 was $1.52 billion, a 2% decline compared to $1.55 billion in 3Q16, mainly due to lower sales of Janumet.

  • 50,000 New Drug Tests Among Brexit Worries for Pharma Companies
    Bloomberg11 days ago

    50,000 New Drug Tests Among Brexit Worries for Pharma Companies

    Global drugmakers from Johnson & Johnson to AstraZeneca Plc warned that potential trade and regulatory hurdles may burden them with a host of additional costs after Britain leaves the European Union.

  • Market Realist13 days ago

    Gauging Novartis’s Valuation This November

    Novartis saw revenues of ~$12.4 billion and EPS of $1.29 for 3Q17, which represents a 2% YoY rise, compared with its revenues of ~$12.1 billion in 3Q16.

  • Benzinga13 days ago

    FDA Decisions In November: The Month In Review

    Rounding out a month marked mostly by positive decisions, FDA announced its approval late for Sublocade, a once-monthly injectable buprenorphine product for the treatment of opioid addiction. U.K.-listed ...

  • What Does AstraZeneca PLC’s (LSE:AZN) Share Price Indicate?
    Simply Wall St.14 days ago

    What Does AstraZeneca PLC’s (LSE:AZN) Share Price Indicate?

    AstraZeneca PLC (LSE:AZN) saw significant share price volatility over the past couple of months on the LSE, rising to the highs of £51.8 and falling to the lows of £45.74.Read More...

  • Capital Cube15 days ago

    ETFs with exposure to AstraZeneca Plc : November 29, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AstraZeneca Plc Here are 5 ETFs with the largest exposure to AZN-US. Comparing the performance and risk of AstraZeneca Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA
    Zacks15 days ago

    AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA

    AstraZeneca's (AZN) Marketing Authorisation Application for label expansion of Tagrisso has been accepted by the European Medicines Agency.

  • Market Realist16 days ago

    Nektar Therapeutics Raised Its Revenue Guidance for 2017

    After the collaboration with Eli Lilly for investigational drug NKTR-358, Nektar Therapeutics (NKTR) increased its 2017 revenue projections to $250 million–$255 million.

  • American City Business Journals16 days ago

    RTP company lands work with AstraZeneca

    Research Triangle Park-based G1 Therapeutics (GTHX) – which raised more than $108 million in its initial public offering earlier this year – has landed work with global biopharmaceutical behemoth AstraZeneca. According to G1, it “will sponsor and conduct the Phase 1b/2 study in collaboration with AstraZeneca.” However, financial terms of the collaboration and resulting study – expected to commence in the first quarter of next year – are not being disclosed.

  • AstraZeneca Files for Label Expansion of Tagrisso in Japan
    Zacks16 days ago

    AstraZeneca Files for Label Expansion of Tagrisso in Japan

    AstraZeneca (AZN) files a regulatory application in Japan to expand the label of Tagrisso for first-line treatment of patients with non-small cell lung cancer.

  • American City Business Journals17 days ago

    AstraZeneca forms joint venture in China

    AstraZeneca said Monday it has formed a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to create a stand-alone company in China to discover, develop and commercialize potential new medicines. The new company, Dizal Pharmaceutical, will be equally owned by AstraZeneca and FIIF, which is managed by the private equity management firm SDIC Fund Management Co. “AstraZeneca has a long-standing and strong commitment to China, which we are reinforcing today with this ground-breaking joint venture,” said Pascal Soriot, CEO of AstraZeneca.

  • AstraZeneca steps up China push with new drug joint venture
    Reuters18 days ago

    AstraZeneca steps up China push with new drug joint venture

    Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund. The stand-alone business, Dizal Pharmaceutical, will be owned equally with the Chinese Future Industry Investment Fund (FIIF), which is part-owned by the China State Development & Investment Corporation, the companies said on Monday. By getting into bed with a local player, AstraZeneca aims to ride a wave of regulatory reform in China's pharmaceuticals sector and get new drugs to market more quickly.

  • Reuters18 days ago

    AstraZeneca steps up China push with new drug joint venture

    Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund. The stand-alone business, Dizal Pharmaceutical, will be owned equally with the Chinese Future Industry Investment Fund (FIIF), which is part-owned by the China State Development & Investment Corporation, the companies said on Monday. By getting into bed with a local player, AstraZeneca aims to ride a wave of regulatory reform in China's pharmaceuticals sector and get new drugs to market more quickly.

  • Nektar (NKTR) Stock Up More than 300% This Year: Here's Why
    Zacks20 days ago

    Nektar (NKTR) Stock Up More than 300% This Year: Here's Why

    Nektar's (NKTR) shares skyrocket in the year so far on a robust pipeline including several study initiations and strategic collaborations.

  • 3 Companies Competing to Gain Lead in Ovarian Cancer Market
    Zacks20 days ago

    3 Companies Competing to Gain Lead in Ovarian Cancer Market

    Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.

  • Top 10 Largest Pharmaceutical Companies By Revenue in 2017
    Insider Monkey21 days ago

    Top 10 Largest Pharmaceutical Companies By Revenue in 2017

    The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]